Kilitch Drugs India Ltd

Kilitch Drugs India Ltd – Closure of Trading Window

AGM Details

• AGM held on 27 August 2026 at 9:00 AM IST via Video Conferencing / OAVM.
• Remote e-voting window ran 20–27 August 2026; results unblocked 27 August 2026.

Ordinary Resolutions

• Adoption of Audited financial statements for year ended 31 March 2026; passed 95% in favour, 5% against.

Special Resolutions

• Approve payment of performance linked pay to executive directors; passed 95% in favour, 5% against.

Director Changes

• Re-appointment of Mr. Mukund P. Mehta as director (retiring by rotation).

Auditor Actions

• Remuneration to Cost Auditor ratified; passed 95% in favour, 5% against.

AGM Details

• 34th AGM held on 27 August 2026 at 9:00 a.m. via VC/OAVM.
• No physical attendance; proxies not allowed due to VC/OAVM format.
• Notice, Directors' Report, and Audited Standalone & Consolidated Financial Statements taken as read.
• Quorum present; meeting chaired by Managing Director Mukund Mehta.
• Attendees included MDs, Independent Directors, CFO, Company Secretary, and auditors.

Issue Overview and Utilisation

• Type: Rights issue of equity shares; objects: capex for Greenfield Pen project and GCP.
• Total issue size: rights issue; no undersubscription or revision reported.
• Main objective: capex for Greenfield Pen project; General Corporate Purposes.
• Utilisation as per offer document: no material deviation.
• Deviations/changes: capex payments delayed pending final inspection.
• Capex funding: partial utilisation; 1.12 crore utilised in Q1 FY27; balance ongoing.
• GCP funds: unutilised at end of Q4 FY26; later utilised in FY27 for capex payments.
• Governance: CA certificate dated 13 Aug 2026; MA reports no deviation.
• Material events: no events affecting viability reported.
• Approvals: explicit approvals not detailed; monitoring indicates no material deviation.
• GCP board approval: not explicitly reported.

Financial results approved

• Standalone unaudited results for quarter ended 30 June 2026 approved
• Consolidated unaudited results for quarter ended 30 June 2026 approved
• Limited Review Report by auditors submitted with results

Audit and compliance

• Independent auditor's review concluded no material misstatement

• Meeting details (date, time, venue) not disclosed in this chunk.

Dematerialisation status

• Dematerialisation requests processed; confirmations issued to depositories; securities listed on exchanges.
• Physical certificates for dematerialisation mutilated and cancelled after verification; depository's name substituted as registered owner.

Meeting Details

• Board meeting on Friday, 15 May 2026.
• Time and location were not disclosed.

Key Agenda Items

• Approve audited standalone financial results for the quarter and year ended 31 March 2026.
• Approve audited consolidated financial results for the quarter and year ended 31 March 2026.

Other Notes

• Trading window closed from 1 April 2026.
• Trading window reopens 48 hours after results are disclosed.